Edition:
India

CSPC Pharmaceutical Group Ltd (1093.HK)

1093.HK on Hong Kong Stock

15.34HKD
18 Apr 2019
Change (% chg)

HK$-0.30 (-1.92%)
Prev Close
HK$15.64
Open
HK$15.50
Day's High
HK$15.62
Day's Low
HK$15.30
Volume
27,875,992
Avg. Vol
42,425,331
52-wk High
HK$26.75
52-wk Low
HK$9.90

Latest Key Developments (Source: Significant Developments)

CSPC Pharmaceutical Group Posts FY Profit Attributable Of HK$3.65 Bln
Monday, 18 Mar 2019 

March 18 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::FY PROFIT ATTRIBUTABLE HK$3.65 BILLION VERSUS HK$2.77 BILLION.FY REVENUE HK$21.03 BILLION VERSUS HK$15.46 BILLION.DECLARED A FINAL DIVIDEND PER SHARE OF HK18 CENTS.  Full Article

CSPC Pharmaceutical Submitted New Drug Application To U.S. FDA For Levoamlodipine Maleate Tablets
Tuesday, 5 Mar 2019 

March 5 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::SUBMITTED NEW DRUG APPLICATION TO U.S. FDA FOR LEVOAMLODIPINE MALEATE TABLETS FOR TREATMENT OF HYPERTENSION.  Full Article

CSPC Pharmaceutical Says Cetrain Financial Media Reported Co Indicated 20 Pct-30 Pct Profit Growth For FY19
Thursday, 10 Jan 2019 

Jan 10 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::CSPC PHARMACEUTICAL SAYS CETRAIN FINANCIAL MEDIA REPORTED THAT COMPANY INDICATED A TARGET GUIDANCE OF 20%-30% PROFIT GROWTH OF GROUP FOR FY 2019.BOARD STATES THAT ANALYST REPORTS FAIRLY REFLECT CURRENT VIEW OF MANAGEMENT.  Full Article

CSPC Pharmaceutical Group'S Unit Enters Agreement With I-Mab Biopharma (Shanghai) Co
Monday, 17 Dec 2018 

Dec 17 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::UNIT ENTERED INTO AN AGREEMENT WITH I-MAB BIOPHARMA (SHANGHAI) CO., LTD..CSPC BAIKE AGREED TO PAY UPFRONT PAYMENT OF RMB15 MILLION & DEVELOPMENT MILESTONE PAYMENTS OF UP TO RMB135 MILLION TO I-MAB.DEAL FOR LICENSING & COMMERCIALIZATION OF LONG-ACTING RECOMBINANT GLP-1 FC FUSION PROTEIN (TG103) FOR INJECTION DEVELOPED BY I-MAB.  Full Article

CSPC Pharmaceutical Group's "Amoxicillin Capsules" Granted Approval By NMPA
Monday, 26 Nov 2018 

Nov 26 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::GROUP'S "AMOXICILLIN CAPSULES" GRANTED APPROVAL BY NMPA FOR PASSING CONSISTENCY EVALUATION.  Full Article

Cspc Pharmaceutical Group Says "Tirofiban Hydrochloride And Sodium Chloride Injection" Granted Drug Registration Approval
Monday, 26 Nov 2018 

Nov 26 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::"TIROFIBAN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION" GRANTED DRUG REGISTRATION APPROVAL.APPROVAL GRANTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PEOPLE'S REPUBLIC OF CHINA.  Full Article

Cspc Pharmaceutical Group Says Product Candidate "Almb-0166" Granted Orphan-Drug Designation By U.S. FDA
Monday, 26 Nov 2018 

Nov 26 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::GROUP'S PRODUCT CANDIDATE "ALMB-0166" GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA.  Full Article

CSPC Pharmaceutical Group Posts 9-Mth Profit Attributable Of HK$2.73 Bln
Monday, 19 Nov 2018 

Nov 19 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::9-MONTH PROFIT ATTRIBUTABLE TO SHAREHOLDERS HK$2.73 BILLION VERSUS HK$2.04 BILLION.9-MONTH TOTAL REVENUE HK$15.85 BILLION VERSUS HK$11.21 BILLION.  Full Article

Cspc Pharmaceutical Enters License Deal With Sinocelltech For Anti-CD20 Monoclonal Antibody
Monday, 8 Oct 2018 

Oct 8 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::ENTERS DEAL WITH SINOCELLTECH TO LICENSE AND COMMERCIALIZE ANTI- CD20 MONOCLONAL ANTIBODY FOR INJECTION DEVELOPED BY SINOCELLTECH.CO TO PAY SINOCELLTECH UPFRONT & DEVELOPMENT MILESTONE PAYMENTS OF UP TO RMB650 MILLION.PURSUANT TO DEAL, CO WILL BE GRANTED EXCLUSIVE RIGHT FOR PRODUCT BY SINOCELLTECH TO APPLY FOR PRODUCT APPROVAL IN CHINA.  Full Article

CSPC Pharmaceutical Group Posts HY Profit Attributable HK$1.85 Bln
Monday, 20 Aug 2018 

Aug 20 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::HY TOTAL REVENUE HK$10.79 BILLION VERSUS HK$7.20 BILLION.HY PROFIT ATTRIBUTABLE HK$1.85 BILLION VERSUS HK$1.31 BILLION.  Full Article